Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
γδT cell infusion agent
- Development stage
- Unknown
- Lead developer
- PersonGen BioTherapeutics
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
γδT cell infusion agent is an adoptive cell therapy developed by PersonGen BioTherapeutics (Suzhou) Co., Ltd. for the treatment of relapsed or refractory acute leukemia, including B-cell lineages, following allogeneic hematopoietic stem cell transplantation (allo-HSCT). The therapy utilizes donor-derived gamma delta (γδ) T cells, which are a specialized subset of T cells that function at the interface of innate and adaptive immunity. These cells recognize tumor-associated antigens and stress-induced ligands in an MHC-independent manner, which allows for potent anti-leukemic effects with a significantly lower risk of graft-versus-host disease (GvHD) compared to conventional αβ T cells. The agent is currently being evaluated in early-phase clinical trials to prevent or treat relapse in post-transplant patients.
- Other names
- gamma delta T cell infusion agentDonor γδT cell infusion
02
Targets
MICB (Major histocompatibility complex class i-related protein B)Phosphoantigen
Beyond the preview
Go deeper on γδT cell infusion agent.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on γδT cell infusion agent.